Genetically modified allergens.
For more than 90 years, allergen-specific immunotherapy, the only causative allergy treatment, has remained basically unchanged. The development of molecular biology techniques has led to the preparation of individual recombinant allergens from the most important allergen sources. Recombinant allergens can be used to determine the individual sensitization profile of allergic patients and have allowed the development of novel therapeutic tools. This article summarizes data on genetically modified recombinant allergen derivatives with reduced allergenic activity, which may be used to improve the safety and efficacy of specific immunotherapy.
Department of Otorhinolaryngology, Vienna General Hospital, Medical University of Vienna, Ebene 8J, Waehringer Guertel 18-20, Vienna A-1090, Austria. verena.niederberger@meduniwien.ac.at
Verena
V
Niederberger
Rudolf
R
Valenta
D000818:Animals; D003888:Desensitization, Immunologic / Q000379:methods*; D005818:Genetic Engineering; D006801:Humans; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000627:therapeutic use*
D011994:Recombinant Proteins